Immuneering Corp

Immuneering Corp: Nasdaq biopharma innovating oncology‑neurology diagnostics & therapies, driving patient outcomes with cutting‑edge science, $348 M market cap.

Immuneering Corp. will present updated overall survival data for its Phase 2a pancreatic cancer trial on September 25, 2025, which could demonstrate a statistically meaningful improvement over existing treatments and position its combination therapy…

Immuneering Corp is a biopharmaceutical company specializing in innovative diagnostic platforms for oncology and neurology, leveraging human data and novel biology to improve disease detection and treatment outcomes.

Immuneering Corp. is a biopharmaceutical company pioneering diagnostic platforms that leverage human data and novel biology to develop personalized therapies for debilitating oncologic and neurologic diseases.

Immuneering Corp. is a biopharmaceutical company pioneering diagnostic platforms that leverage human data and novel biology to develop new therapies for debilitating oncologic and neurologic diseases.

Immuneering Corp recently participated in the 24th Annual Needham Virtual Healthcare Conference, highlighting its commitment to advancing diagnostic platforms for severe oncologic and neurologic diseases.